Interest in, willingness-to-pay for and willingness-to-recommend genetic testing for prostate cancer among affected men after radical prostatectomy
This study aimed to gain insight into men ’s attitudes in genetic testing for PCa. 4699 men with PCa from the German multicenter prospective database “Familial Prostate Cancer” were included. Interest in, Willingness-to-pay for and Willingness-to-recommend a genetic test for PCa were quantified. Associations with several sociodemograp hic and psychosocial variables were evaluated by logistic regression. 76.8% of the affected men with a median follow-up of 12.9 years were interested in a genetic test for PCa. Newly identified variables significantly associated with interest were having sons (OR 1.66, p
CONCLUSIONS Eriocalyxin B induces apoptosis and autophagy involving the Akt/mTOR pathway in prostate cancer cells in vitro. These findings provide evidence for Eriocalyxin B as a potent therapeutic for the treatment of prostate cancer. PMID: 31714902 [PubMed - in process]
Publication date: Available online 12 November 2019Source: Progress in NeurobiologyAuthor(s): Joseph H. Neale, Tatsuo YamamotoAbstractN-Acetylaspartylglutamate (NAAG) is the third most prevalent neurotransmitter in the mammalian nervous system, yet its therapeutic potential is only now being fully recognized. Drugs that inhibit the inactivation of NAAG by glutamate carboxypeptidase II (GCPII) increase its extracellular concentration and its activation of its receptor, mGluR3. These drugs warrant attention, as they are effective in animal models of several clinical disorders including stroke, traumatic brain injury and schi...
Sepsis affects around 260,000 people a year in the UK and 1.7million in the US. It causes more avoidable deaths than breast, bowel and prostate cancer combined.
Contrast developer Guerbet has signed a strategic partnership with healthcare...Read more on AuntMinnie.comRelated Reading: Guerbet, IBM partner on AI for prostate cancer Guerbet revenues slow in 2nd quarter Guerbet wins group purchasing agreement from Premier Guerbet opens manufacturing site for Lipiodol Guerbet releases new version of Contrast&Care
Authors: Ghashghaei M, Kucharczyk M, Elakshar S, Muanza T, Niazi T Abstract Background: Prostate cancer (pca) is the most common non-dermatologic cancer and the 3rd leading cause of male cancer mortality in Canada. In patients with high-risk localized or recurrent pca, management typically includes the combination of long-term androgen deprivation therapy (adt) and radiotherapy (rt). New androgen-receptor-axis targeted therapies (arats), which await validation, offer an option to intensify therapy. Methods: In this narrative review, we report the relevant history that has supported combining adt with rt. The li...
CONCLUSIONS: In France, end-of-life management of men with PCa, regardless of the cause of death, is centered on SSH and HPC, essentially at the time of death. Certain indicators of end-of-life management were particular high. LEVEL OF EVIDENCE: 4. PMID: 31708329 [PubMed - as supplied by publisher]
Journal Name: Clinical Chemistry and Laboratory Medicine (CCLM) Issue: Ahead of print
ACS Applied Materials&InterfacesDOI: 10.1021/acsami.9b15195
(Medical College of Georgia at Augusta University) A transcription factor that aids neuron function also appears to enable a cell conversion in the prostate gland that can make an already recurrent cancer even more deadly, scientists say.
Publication date: Available online 12 November 2019Source: European UrologyAuthor(s): Guillaume Ploussard